MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT04630808 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

696

Enrollment

INDUSTRY

Sponsor class

Conditions

Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: NCX 470 0.1%
DRUG: Latanoprost 0.005%

Sponsor

Nicox Ophthalmics, Inc.